Logo image
Back
Measurement of treatment response to sertraline in depressed multiple sclerosis patients using the Carroll scale
Journal article   Peer reviewed

Measurement of treatment response to sertraline in depressed multiple sclerosis patients using the Carroll scale

Thomas F. Scott, Paul Nussbaum, Harry McConnell and Paul Brill
Neurological research (New York), v 17(6), pp 421-422
01 Dec 1995
DOI: https://doi.org/10.1080/01616412.1995.11740355
PMID: 8622794
Featured in Collection :   UN Sustainable Development Goals @ Drexel

Abstract

depression Multiple sclerosis neuropsychology serotonin sertraline
We studied 11 patients with stable multiple sclerosis (MS) with major depression in terms of response to Sertraline at 100 mg q.d. in an open label trial. Patients were evaluated with self assessment measurements (Carroll scale) prior to and during treatment Only one patient discontinued the drug during the three month treatment trial, and this was due to perceived lack of efficacy by the patient. The remainder of the patients completed at least three months of treatment and had significant improvement in depressive symptoms by self assessment measurements. No patients experienced side effects. Sertraline appears to be well tolerated and effective in treatment of major depression in AAS. The Carroll scale is an easily administered means of assessing treatment response, and correlated highly with our clinical impressions. [Neurol Res 1995; 17: 421-422]

Metrics

13 Record Views
52 citations in Web of Science
63 citations in Scopus

Details

UN Sustainable Development Goals (SDGs)

This publication has contributed to the advancement of the following goals:

#3 Good Health and Well-Being

InCites Highlights

Data related to this publication, from InCites Benchmarking & Analytics tool:

Collaboration types
Domestic collaboration
Web of Science research areas
Clinical Neurology
Neurosciences
Logo image